Impact of Expanded Medicare Reimbursement for Telemedicine on Use of Telemedicine Modalities to Access Cancer Care

项目摘要 弗雷德和帕梅拉·巴菲特癌症中心（Buffett Cancer Center或BCC），一家NCI指定的癌症中心 自1984年以来，致力于基础，转化，临床和人口科学研究，全面 教育计划，并在我们的集水区（内布拉斯加州）服务不足的社区外展。新 BCC综合癌症研究和护理设施将癌症中心控制的研究空间增加了1.7倍 （总面积400，000平方英尺），创造一个促进科学创新和跨学科的环境 合作。癌症中心完全融入了大学及其附属的医疗保健网络， 内布拉斯加州医学（NM），主任直接向联合国医学委员会校长兼首席执行官NM报告， 被任命为BCC总医师。自去年以来，设立了两个癌症中心领导职位。 审查，副主任和副主任社区外联和参与（COE），与后者 领导努力减少癌症负担和内布拉斯加州不同社区的差异。BCC还 任命了四名新的高级领导人，并取消了双重领导角色，以促进临床和翻译 research.完成了BCC临床试验办公室的集中、扩展和重组， 安装了新的CTMS（OnCore），最终使干预性临床试验的累积增加了1.8倍。 通过增加新的临床前成像共享资源以及 若干新资源（例如，代谢组学，类器官，患者衍生模型，组织微阵列，合成 药物化学和计算化学）。BCC有三个研究项目：癌症 生物学计划（CBP）;目标，调节剂和交付计划（TMDP）;和GI癌症计划（GICP）。 CBP和TMDP这两个项目更改了名称，反映了其任务、主题和活动的战略调整。 和会员资格。在当前的资助期内招募了28名成员，BCC拥有强大的轨道 由14个多学科奖项（P01，P50，P20，U奖）支持的临床和转化研究记录; 6个来自NCI）和16个新的MPI奖项（11个来自NCI）。BCC中与癌症相关的同行评审研究资金 增加1.4倍，达到2530万美元（年度直接成本），NCI资金增加1.3倍，达到1250万美元（年度直接成本 自上次审查以来的费用。

PROJECT SUMMARY The Fred & Pamela Buffett Cancer Center (Buffett Cancer Center or BCC), an NCI-designated Cancer Center since 1984, is committed to basic, translational, clinical and population science research, comprehensive educational programs, and outreach to underserved communities in our catchment area (Nebraska). The new BCC integrated cancer research and care facility increased Cancer Center-controlled research space 1.7-fold (total 400,000 sq ft), creating an environment which fosters scientific innovation and transdisciplinary collaborations. The Cancer Center is fully integrated into the university and its affiliated healthcare network, Nebraska Medicine (NM), with the Director reporting directly to the UNMC Chancellor and CEO NM and appointed BCC Physician-in-Chief. Two Cancer Center leadership positions were established since the last review, Deputy Director and Associate Director for Community Outreach and Engagement (COE), with the latter leading efforts to reduce cancer burden and disparities in diverse communities across Nebraska. The BCC also appointed four new senior leaders and eliminated dual leadership roles to promote clinical and translational research. The centralization, expansion and reorganization of the BCC Clinical Trials Office was completed and a new CTMS (OnCore) installed, culminating in a 1.8-fold increase in accrual to interventional clinical trials. Research infrastructure was enhanced by the addition of a new Preclinical Imaging Shared Resource as well as several new resources (e.g., Metabolomics, Organoids, Patient-Derived Models, Tissue Microarrays, Synthetic and Medicinal Chemistry, and Computational Chemistry). The BCC has three Research Programs: Cancer Biology Program (CBP); Targets, Modulators and Delivery Program (TMDP); and GI Cancer Program (GICP). Two programs, CBP and TMDP, changed names, reflecting the strategic realignment of their missions, themes and memberships. With 28 Members recruited during the current funding period, the BCC has a robust track record of clinical and translational research supported by 14 multidisciplinary awards (P01, P50, P20s, U awards; 6 from NCI) and 16 new MPI awards (11 from NCI). Cancer-relevant peer-reviewed research funding in the BCC increased 1.4-fold to $25.3M (Annual Direct Costs) and NCI funding increased 1.3-fold to $12.5 M (Annual Direct Costs) since our last review.